ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


Published online before print February 14, 2007
Eur Respir J 2007, doi:10.1183/09031936.00147806
This Article
Right arrow Full Text (Rapid PDF)
Right arrow All Versions of this Article:
29/6/1127    most recent
09031936.00147806v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Permissions
Right arrowRequest Permissions
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Siempos, I.I.
Right arrow Articles by Falagas, M.E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Siempos, I.I.
Right arrow Articles by Falagas, M.E.

ORIGINAL ARTICLE

Macrolides, quinolones, and amoxicillin/clavulanate for chronic bronchitis: a meta-analysis

I.I. Siempos 1, G. Dimopoulos 2, I.P. Korbila 1, K. Manta 1, M.E. Falagas 3

1 Alfa Institute of Biomedical Sciences (AIBS), Athens, Greece
2 Alfa Institute of Biomedical Sciences (AIBS), Athens, Greece; and Intensive Care Unit, "Attikon" University Hospital, Athens, Greece
3 Alfa Institute of Biomedical Sciences (AIBS), Athens, Greece; Dept of Medicine, Henry Dunant Hospital, Athens, Greece; and Dept of Medicine, Tufts University School of Medicine, Boston, Massachusetts, USA


   Abstract

We evaluated the comparative effectiveness and safety of macrolides, quinolones, and amoxicillin/clavulanic acid (A/C) for the treatment of patients with acute bacterial exacerbation of chronic bronchitis (ABECB).

PubMed, Current Contents, and the Cochrane Central Register of Controlled Trials were searched to identify relevant randomized controlled trials (RCTs).

Nineteen RCTs (20 comparisons) were included. There was no difference regarding treatment success in intention-to-treat and clinically evaluable patients between macrolides and quinolones, A/C and quinolones or A/C and macrolides. The treatment success in microbiologically evaluable patients was lower for macrolides compared with quinolones (OR=0.47, 95% CI 0.31-0.69). Less quinolone-recipients experienced a recurrence of ABECB after resolution of the initial episode compared with macrolide-recipients during the 26-week period after therapy. Adverse effects in general were similar between macrolides and quinolones. Administration of A/C was associated with more adverse effects (mainly diarrhea) than quinolones (OR=1.36, 95% CI 1.01-1.85).

Macrolides, quinolones, and A/C may be considered equivalent for the treatment of patients with ABECB in terms of short-term effectiveness. Quinolones are associated with better microbiological success and fewer recurrence of ABECB than macrolides, while A/C with more adverse effects than both comparators.

Keywords:  Chronic obstructive pulmonary disease, haemophilus influanzea, moraxella catarrhalis, pseudomonas aeruginosa, streptococcus pneumoniae




This article has been cited by other articles:


Home page
Am. J. Respir. Crit. Care Med.Home page
J. M. A. Daniels, D. Snijders, C. S. de Graaff, F. Vlaspolder, H. M. Jansen, and W. G. Boersma
Antibiotics in Addition to Systemic Corticosteroids for Acute Exacerbations of Chronic Obstructive Pulmonary Disease
Am. J. Respir. Crit. Care Med., January 15, 2010; 181(2): 150 - 157.
[Abstract] [Full Text] [PDF]


Home page
J Antimicrob ChemotherHome page
M. E. Falagas, S. G. Avgeri, D. K. Matthaiou, G. Dimopoulos, and I. I. Siempos
Short- versus long-duration antimicrobial treatment for exacerbations of chronic bronchitis: a meta-analysis
J. Antimicrob. Chemother., September 1, 2008; 62(3): 442 - 450.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
K. C. Chang and C. C. Leung
Meta-analysis may not be practicable for guiding antibiotic therapy
Eur. Respir. J., April 1, 2008; 31(4): 906 - 907.
[Full Text] [PDF]


Home page
Eur Respir JHome page
I. I. Siempos, G. Dimopoulos, and M. E. Falagas
From the authors
Eur. Respir. J., April 1, 2008; 31(4): 907 - 908.
[Full Text] [PDF]


Home page
Eur Respir JHome page
A. Singh
Quinolones to treat acute bacterial exacerbation of chronic bronchitis in TB endemic areas: a word of caution
Eur. Respir. J., December 1, 2007; 30(6): 1233 - 1233.
[Full Text] [PDF]


Home page
Proc Am Thorac SocHome page
F. J. Martinez
Pathogen-directed Therapy in Acute Exacerbations of Chronic Obstructive Pulmonary Disease
Proceedings of the ATS, December 1, 2007; 4(8): 647 - 658.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
P. Laohaburanakit, G. Dimopoulos, I. I. Siempos, M. E. Falagas, and R. Irwin
Antibiotic Use in Acute Exacerbations of Chronic Bronchitis
Chest, December 1, 2007; 132(6): 2063 - 2064.
[Full Text] [PDF]


Home page
Eur Respir JHome page
M. Miravitlles, B. Celli, and A. Anzueto
Antibiotics for chronic bronchitis: a meta-analysis that speaks only four languages
Eur. Respir. J., October 1, 2007; 30(4): 815 - 815.
[Full Text] [PDF]


Home page
Eur Respir JHome page
I. I. Siempos, G. Dimopoulos, and M. E. Falagas
From the authors
Eur. Respir. J., October 1, 2007; 30(4): 815 - 816.
[Full Text] [PDF]


Home page
ChestHome page
G. Dimopoulos, I. I. Siempos, I. P. Korbila, K. G. Manta, and M. E. Falagas
Comparison of First-Line With Second-Line Antibiotics for Acute Exacerbations of Chronic Bronchitis: A Metaanalysis of Randomized Controlled Trials
Chest, August 1, 2007; 132(2): 447 - 455.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2007 by the European Respiratory Society.